Renal pelvis carcinoma
disease diseaseOn this page
Also known as cancer of renal pelviscarcinoma of kidney pelviscarcinoma of renal pelviscarcinoma of the kidney pelviscarcinoma of the renal pelviskidney pelvis carcinomakidney renal pelvis cancermalignant neoplasm of renal pelvismalignant renal pelvis neoplasmmalignant tumour of renal pelvisrenal pelvis cancer
Summary
Renal pelvis carcinoma (MONDO:0005519) is a cancer with 1 GWAS associations across 1 studies and 33 clinical trials. Top therapeutic interventions include cabozantinib, cisplatin, and enfortumab vedotin. A subtype of renal carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- GWAS associations: 1
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | renal pelvis carcinoma |
| Mondo ID | MONDO:0005519 |
| EFO | EFO:0005582 |
| DOID | DOID:4919 |
| ICD-10-CM | C65 |
| NCIT | C6142 |
| SNOMED CT | 363457009 |
| UMLS | C1335749 |
| MedGen | 235548 |
| Anatomy (UBERON) | UBERON:0001224 |
| Is cancer (heuristic) | yes |
Also known as: cancer of renal pelvis · carcinoma of kidney pelvis · carcinoma of renal pelvis · carcinoma of the kidney pelvis · carcinoma of the renal pelvis · kidney pelvis carcinoma · kidney renal pelvis cancer · malignant neoplasm of renal pelvis · malignant renal pelvis neoplasm · malignant tumour of renal pelvis · renal pelvis cancer · renal pelvis carcinoma
Data availability: 1 GWAS association (1 study) · 7 cell lines.
Disease family
This is a subtype of renal carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › kidney cancer › renal carcinoma › renal pelvis carcinoma
Related subtypes (2): kidney carcinoma in situ, renal cell carcinoma
Subtypes (4): renal pelvis adenocarcinoma, renal pelvis squamous cell carcinoma, renal pelvis urothelial carcinoma, carcinoma in situ of renal pelvis
Genetics & variants
GWAS landscape
1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs758052649 | 2e-07 | VENTXP1 - AMZ2P3 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90651979 | Liu TY | 2025 | 432 | 235,128 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs758052649 | X | 26910486 | TAAA>T,TAA | intergenic_variant | VENTXP1 - AMZ2P3 | 2e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| Not specified | 9 |
| PHASE1 | 7 |
| PHASE3 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05092958 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study |
| NCT06661720 | PHASE3 | RECRUITING | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer |
| NCT00942331 | PHASE3 | COMPLETED | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
| NCT03237780 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
| NCT04848519 | PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
| NCT04940299 | PHASE2 | ACTIVE_NOT_RECRUITING | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT05756569 | PHASE2 | RECRUITING | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology |
| NCT00661609 | PHASE2 | COMPLETED | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer |
| NCT00749892 | PHASE2 | COMPLETED | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer |
| NCT01282463 | PHASE2 | COMPLETED | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma |
| NCT02665039 | PHASE2 | COMPLETED | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function |
| NCT03397394 | PHASE2 | TERMINATED | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
| NCT03513952 | PHASE2 | COMPLETED | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma |
| NCT03617913 | PHASE2 | COMPLETED | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer |
| NCT04398368 | PHASE2 | TERMINATED | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT04963153 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy |
| NCT06238479 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors |
| NCT06465069 | PHASE1 | RECRUITING | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors |
| NCT01182168 | PHASE1 | COMPLETED | Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies |
| NCT01844947 | PHASE1 | COMPLETED | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
| NCT02300610 | PHASE1 | COMPLETED | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer |
| NCT02812420 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
| NCT00902590 | Not specified | ACTIVE_NOT_RECRUITING | A Genotype-Phenotype Urothelial Cancer Registry |
| NCT05059444 | Not specified | RECRUITING | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation |
| NCT06427993 | Not specified | NOT_YET_RECRUITING | Urine DNA Methylation Detection for Hematuria Evaluation |
| NCT06469229 | Not specified | NOT_YET_RECRUITING | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria |
| NCT06652009 | Not specified | RECRUITING | Radical Radiotherapy Versus Radical Surgery for UTUC |
| NCT01138124 | Not specified | COMPLETED | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) |
| NCT01236053 | Not specified | COMPLETED | Cancer in Patients With Gabapentin (GPRD) |
| NCT03662204 | Not specified | COMPLETED | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors |
| NCT05739812 | Not specified | UNKNOWN | The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 4 |
| CISPLATIN | 4 | 3 |
| ENFORTUMAB VEDOTIN | 4 | 2 |
| TIVOZANIB | 4 | 2 |
| VINFLUNINE | 4 | 2 |
| AVELUMAB | 4 | 1 |
| ERDAFITINIB | 4 | 1 |
| ERIBULIN MESYLATE | 4 | 1 |
| GEMCITABINE | 4 | 1 |
| RELATLIMAB | 4 | 1 |
| RUCAPARIB | 4 | 1 |
| AZD-4877 | 2 | 1 |
| ICRUCUMAB | 2 | 1 |